Gulfstream Daily Brief

Regulatory intelligence and policy · Issue 033

FDA advances eCTD implementation and rare disease framework discussions, EMA opens herbal interaction consultation

Electronic submission standards lead today’s brief, alongside opportunities to inform emerging approaches to rare disease therapies and herbal medicinal product interactions.

By Scott Morvay, Founder October 16, 2026 Official sources linked

FDA

FDA announces enforcement of new eCTD validation criteria

FDA announced that CDER and CBER will begin rejecting submissions that fail specified high severity validations for eCTD versions 3.2.2 and 4.0.

Read the official source

FDA

FDA supports forward compatibility for eCTD 4.0

CDER and CBER announced support for forward compatibility in electronic submissions based on eCTD version 4.0.

Read the official source

FDA

FDA seeks input on a fit for purpose rare disease framework

FDA announced a public meeting focused on developing a framework for rare disease therapy development and review, with opportunities for meeting comments and written feedback through a public docket.

Read the official source

EMA

EMA opens consultation on herbal medicinal product interactions

EMA published a draft reflection paper on investigating drug interactions involving herbal medicinal products and opened it for consultation.

Read the official source

Why this matters

Regulatory teams should track the operational consequences of FDA’s eCTD validation and compatibility notices. The FDA rare disease initiative and EMA consultation also provide formal opportunities to help shape developing regulatory approaches in areas where evidence generation and review can be complex.

Scott Morvay

Founder, Gulfstream Intelligence

This brief provides general regulatory news and educational information. It is not legal or regulatory advice.